![]() 2,4′-dibromoacetophenone structure
|
Common Name | 2,4′-dibromoacetophenone | ||
---|---|---|---|---|
CAS Number | 99-73-0 | Molecular Weight | 277.941 | |
Density | 1.8±0.1 g/cm3 | Boiling Point | 310.4±22.0 °C at 760 mmHg | |
Molecular Formula | C8H6Br2O | Melting Point | 108-110 °C(lit.) | |
MSDS | Chinese USA | Flash Point | 114.1±8.9 °C | |
Symbol |
![]() GHS05 |
Signal Word | Danger |
Name | 2,4'-Dibromoacetophenone |
---|---|
Synonym | More Synonyms |
Density | 1.8±0.1 g/cm3 |
---|---|
Boiling Point | 310.4±22.0 °C at 760 mmHg |
Melting Point | 108-110 °C(lit.) |
Molecular Formula | C8H6Br2O |
Molecular Weight | 277.941 |
Flash Point | 114.1±8.9 °C |
Exact Mass | 275.878540 |
PSA | 17.07000 |
LogP | 2.95 |
Vapour Pressure | 0.0±0.7 mmHg at 25°C |
Index of Refraction | 1.604 |
Stability | Stable. Incompatible with strong bases, strong reducing agents, strong oxidizing agents. |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
![]() GHS05 |
---|---|
Signal Word | Danger |
Hazard Statements | H314 |
Precautionary Statements | P280-P305 + P351 + P338-P310 |
Personal Protective Equipment | Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
Hazard Codes | C:Corrosive; |
Risk Phrases | R34 |
Safety Phrases | S26-S36/37/39-S45 |
RIDADR | UN 3261 8/PG 2 |
WGK Germany | 2 |
RTECS | AM6950000 |
Packaging Group | III |
Hazard Class | 8 |
HS Code | 29147090 |
Precursor 7 | |
---|---|
DownStream 10 | |
HS Code | 2914700090 |
---|---|
Summary | HS: 2914700090 halogenated, sulphonated, nitrated or nitrosated derivatives of ketones and quinones, whether or not with other oxygen function Tax rebate rate:9.0% Supervision conditions:none VAT:17.0% MFN tariff:5.5% General tariff:30.0% |
Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds.
J. Med. Chem. 54 , 4042-56, (2011) Development of kinase-targeted therapies for central nervous system (CNS) diseases is a great challenge. Glycogen synthase kinase 3 (GSK-3) offers a great potential for severe CNS unmet diseases, bein... |
|
Identification and characterisation of novel inhibitors on extrinsic tenase complex from Bungarus fasciatus (banded krait) venom.
Thromb. Haemost. 112(4) , 700-15, (2014) Snake venoms are excellent sources of pharmacologically active proteins and peptides, and hence are potential sources of leads for drug developments. It has been previously established that krait (Bun... |
|
Effects of vipoxin and its components on HepG2 cells.
Toxicon 94 , 36-44, (2015) Snake venom Phospholipases A2 (svPLA2) are among the main toxic venom components with a great impact on different tissues and organs based on their catalytic specificity and a variety of pharmacologic... |
2-Bromo-1-(4-bromophenyl)ethanone |
BromophenacylBromide |
PBPB |
2,4'-Dibromoacetophenone |
p-Bromophenacyl bromide |
2-bromo-1-(4-bromophenyl)-1-ethanone |
Ethanone, 2-bromo-1- (4-bromophenyl)- |
2-bromo-4'-bromoacetophenone |
2,4`-Dibromoacetophenone |
2,4'-Dibromo-acetophenone |
α,p-Dibromoacetophenone |
Ethanone, 2-bromo-1-(4-bromophenyl)- |
2,3-DIFLUOROBENZOTRIFLUORIDE |
2,4′-dibromoacetophenone |
MFCD00000200 |
p-α-Dibromoacetophenone |
2-bromo-1-(4-bromophenyl)ethan-1-one |
EINECS 202-783-6 |
p-bromophenacyl-8 |